JP2008504304A5 - - Google Patents

Download PDF

Info

Publication number
JP2008504304A5
JP2008504304A5 JP2007518382A JP2007518382A JP2008504304A5 JP 2008504304 A5 JP2008504304 A5 JP 2008504304A5 JP 2007518382 A JP2007518382 A JP 2007518382A JP 2007518382 A JP2007518382 A JP 2007518382A JP 2008504304 A5 JP2008504304 A5 JP 2008504304A5
Authority
JP
Japan
Prior art keywords
alkyl
group
compound
heteroalkyl
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007518382A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008504304A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/023275 external-priority patent/WO2006004925A1/en
Publication of JP2008504304A publication Critical patent/JP2008504304A/ja
Publication of JP2008504304A5 publication Critical patent/JP2008504304A5/ja
Pending legal-status Critical Current

Links

JP2007518382A 2004-06-28 2005-06-28 テトラヒドロキナゾリン−4(3h)−オン関連、及びテトラヒドロピリド[2,3−d]ピリミジン−4(3h)−オン関連化合物、組成物、及びそれらの使用方法 Pending JP2008504304A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58382304P 2004-06-28 2004-06-28
PCT/US2005/023275 WO2006004925A1 (en) 2004-06-28 2005-06-28 Tetrahydroquinazolin-4(3h)-one-related and tetrahydropyrido[2,3-d]pyrimidin-4(3h)-one-related compounds, compositions and methods for their use

Publications (2)

Publication Number Publication Date
JP2008504304A JP2008504304A (ja) 2008-02-14
JP2008504304A5 true JP2008504304A5 (enExample) 2008-08-14

Family

ID=34982539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007518382A Pending JP2008504304A (ja) 2004-06-28 2005-06-28 テトラヒドロキナゾリン−4(3h)−オン関連、及びテトラヒドロピリド[2,3−d]ピリミジン−4(3h)−オン関連化合物、組成物、及びそれらの使用方法

Country Status (7)

Country Link
US (1) US7375102B2 (enExample)
EP (1) EP1765818A1 (enExample)
JP (1) JP2008504304A (enExample)
AU (1) AU2005260630A1 (enExample)
CA (1) CA2572084A1 (enExample)
MX (1) MX2007000044A (enExample)
WO (1) WO2006004925A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7939538B2 (en) * 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
TW200714610A (en) * 2005-02-16 2007-04-16 Univ Maryland CXCR3 is a gliadin receptor
EP1889622A4 (en) * 2005-05-31 2009-12-23 Ono Pharmaceutical Co SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF
ATE474829T1 (de) * 2005-06-27 2010-08-15 Amgen Inc Entzündungshemmende arylnitrilverbindungen
WO2009094168A1 (en) * 2008-01-22 2009-07-30 Amgen Inc. Cxcr3 antagonists
EP2358684B8 (en) 2008-10-20 2014-10-22 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Low molecular weight thyroid stimulating hormone receptor (tshr) agonists
CN102791705B (zh) 2010-04-08 2016-08-03 美国政府(由卫生和人类服务部的部长所代表) 用于tsh受体的反向激动剂和中性拮抗剂
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
US9072738B2 (en) 2011-06-27 2015-07-07 Parion Sciences, Inc. Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
WO2013010092A1 (en) 2011-07-13 2013-01-17 Novartis Ag 4-oxo-3,5,7,8-tetrahydro-4h-pyrano {4,3-d} pyrminidinyl compounds for use as tankyrase inhibitors
US9181266B2 (en) 2011-07-13 2015-11-10 Novartis Ag 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
MX2014000536A (es) 2011-07-13 2014-12-05 Novartis Ag Compuestos de 4-piperidinilo para usarse como inhibidores de tanquirasa.
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EA201990616A3 (ru) 2012-05-29 2019-12-30 Парион Сайэнс, Инк. Дендримероподобные аминоамиды, обладающие активностью блокаторов натриевых каналов, для лечения сухости глаз и других заболеваний слизистых оболочек
CN108658876A (zh) 2012-12-17 2018-10-16 帕里昂科学公司 3,5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
CN105073717B (zh) 2012-12-17 2018-05-22 帕里昂科学公司 可用于治疗由黏膜水化不足造成的疾病的氯-吡嗪甲酰胺衍生物
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
EP4066834A1 (en) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP7226321B2 (ja) * 2017-09-14 2023-02-21 住友金属鉱山株式会社 近赤外線吸収繊維およびこれを用いた繊維製品、並びにそれらの製造方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0481614A1 (en) 1990-10-01 1992-04-22 Merck & Co. Inc. Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists
US5202322A (en) * 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
US5256667A (en) * 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
US5756502A (en) * 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
US5719144A (en) * 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1996028444A1 (en) * 1995-03-15 1996-09-19 Pfizer Inc. 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS
US6140064A (en) * 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
FR2778662B1 (fr) * 1998-05-12 2000-06-16 Adir Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU7080500A (en) 1999-08-27 2001-03-26 Chemocentryx, Inc. Compounds and methods for modulating cxcr3 function
EP1216234B1 (en) * 1999-09-16 2004-12-29 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
BR0015110A (pt) 1999-10-27 2002-07-02 Cytokinetics Inc Métodos de tratamento de doenças de proliferação celular, de tratamento de um distúrbio associado com a atividade da cinesina ksp, de inibição da cinesina ksp, de triagem de moduladores da cinesina kps e de triagem de compostos que se ligam na cinesina ksp, e, compostos
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
US6964967B2 (en) * 2000-12-11 2005-11-15 Amgen, Inc. Substituted pyrido[2,3-d]pyrimidines and methods for their use
US6794379B2 (en) * 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
ES2361403T3 (es) 2002-03-07 2011-06-16 X-Ceptor Therapeutics, Inc. Moduladores de quinazolinona de receptores nucleares.
WO2003094839A2 (en) * 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
US20040242498A1 (en) 2003-02-27 2004-12-02 Collins Tassie L. CXCR3 antagonists
US7183413B2 (en) 2003-04-11 2007-02-27 Taigen Biotechnology Aminoquinoline compounds

Similar Documents

Publication Publication Date Title
JP2008504304A5 (enExample)
JP2008504301A5 (enExample)
KR102034618B1 (ko) Dna 알킬화제
ES2280768T3 (es) Inhibidores de histona desacetilasa.
KR102093608B1 (ko) 이미다조피리딘 화합물
JP2024534526A (ja) ピリジン系誘導体及びその使用
JP2017511357A5 (enExample)
JP2008510828A5 (enExample)
JP2009525287A (ja) ウイルスポリメラーゼインヒビター
JP2013523803A5 (enExample)
JP2008546843A5 (enExample)
WO2003064410A1 (en) Novel 1,2,4-triazole compound
JP2006518341A (ja) ヒストンデアセチラーゼ(hdac)阻害剤としてのヒドロキサム酸誘導体
JP2011502956A5 (enExample)
JP2010525023A5 (enExample)
CN101426766A (zh) 用作mek抑制剂的新颖的杂芳基取代的芳基氨基吡啶衍生物
JP2007524696A5 (enExample)
JP2015508823A5 (enExample)
JP2016512515A5 (enExample)
JP2009524691A5 (enExample)
JP2016500107A5 (ja) グルタミナーゼ阻害剤およびその使用方法
JP2013507355A (ja) キサンチンオキシダーゼ阻害剤として効果的な新規化合物、その製造方法及びそれを含有する医薬組成物
AU2002238855B2 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
KR20110133049A (ko) 항암 약물로서의 니코틴아미드 유도체, 그의 제조법 및 그의 치료 용도
AU2007270083A1 (en) New pyridine analogues